Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy?

Open access
Kateb, Babak, Chiu, Katherine, Black, Keith L., Yamamoto, Vicky, Khalsa, Bhavraj, Ljubimova, Julia Y., Ding, Hui, Patil, Rameshwar, Portilla-Arias, Jose Antonio, Modo, Mike, Moore, David F., Farahani, Keyvan, Okun, Michael S., Prakash, Neal, Neman, Josh, Ahdoot, Daniel, Grundfest, Warren, Nikzad, Shouleh, Heiss, John D.·2011·NeuroImage

Abstract

Nanotechnology is the design and assembly of submicroscopic devices called nanoparticles, which are 1–100 nm in diameter. Nanomedicine is the application of nanotechnology for the diagnosis and treatment of human disease. Disease-specific receptors on the surface of cells provide useful targets for nanoparticles. Because nanoparticles can be engineered from components that (1) recognize disease at the cellular level, (2) are visible on imaging studies, and (3) deliver therapeutic compounds, nanotechnology is well suited for the diagnosis and treatment of a variety of diseases. Nanotechnology will enable earlier detection and treatment of diseases that are best treated in their initial stages, such as cancer. Advances in nanotechnology will also spur the discovery of new methods for delivery of therapeutic compounds, including genes and proteins, to diseased tissue. A myriad of nanostructured drugs with effective site-targeting can be developed by combining a diverse selection of targeting, diagnostic, and therapeutic components. Incorporating immune target specificity with nanostructures introduces a new type of treatment modality, nano-immunochemotherapy, for patients with cancer. In this review, we will discuss the development and potential applications of nanoscale platforms in medical diagnosis and treatment. To impact the care of patients with neurological diseases, advances in nanotechnology will require accelerated translation to the fields of brain mapping, CNS imaging, and nanoneurosurgery. Advances in nanoplatform, nano-imaging, and nano-drug delivery will drive the future development of nanomedicine, personalized medicine, and targeted therapy. We believe that the formation of a science, technology, medicine law–healthcare policy (STML) hub/center, which encourages collaboration among universities, medical centers, US government, industry, patient advocacy groups, charitable foundations, and philanthropists, could significantly facilitate such advancements and contribute to the translation of nanotechnology across medical disciplines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuroimage.2010.01.105

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 188

Metadata

Authors
Kateb, B., Chiu, K., Black, K. L., Yamamoto, V., Khalsa, B., Ljubimova, J. Y., Ding, H., Patil, R., Portilla-Arias, J. A., Modo, M., Moore, D. F., Farahani, K., Okun, M. S., Prakash, N., Neman, J., Ahdoot, D., Grundfest, W., Nikzad, S., & Heiss, J. D.
Venue
NeuroImage
Publisher
Elsevier BV
Published
2011-01
Volume
54
Pages
S106-S124
ISSN
1053-8119 (ISSN-L)
OpenAlex
W2039581700
Cited by
188
References
10
FWCI
10.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy? https://app.cochat.ai/papers/10.1016/j.neuroimage.2010.01.105
The paper
Kateb, B., Chiu, K., Black, K. L., Yamamoto, V., Khalsa, B., Ljubimova, J. Y., Ding, H., Patil, R., Portilla-Arias, J. A., Modo, M., Moore, D. F., Farahani, K., Okun, M. S., Prakash, N., Neman, J., Ahdoot, D., Grundfest, W., Nikzad, S., & Heiss, J. D. (2011). Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy? NeuroImage. https://doi.org/10.1016/j.neuroimage.2010.01.105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.